💊Cancer drug approval with immature OS data
The Lancet Oncology

🚨Among studies with OS as an endpoint (n=95), 41% (n=39) had immature OS data when approved

🚨Of those, only 32% (n=12) showed OS benefit when the data became mature

⁉️Balance between ensuring patients with unmet…

📖🦠Gastric microbiota and gastric cancer
ESMO - Eur. Oncology

➡️Stomach relatively has a lower microbial load
🚨However, increased gastric pH (>4) and bacterial overgrowth (e.g. long-term PPI use, H2 blockers or chronic gastritis) > change in gastric microbiota
🚨Gastric microbiota and…

Emre Yekedüz , Yüksel Ürün 🇹🇷and team Sati Coskun Yazgan, Erman Akkus answer an important question for our patients with #ProstateCancer

OncoAlert 🚨

Cancer therapy with antibodies

An excellent review providing a comprehensive overview of therapeutic antibodies used in cancer treatment👇

OncoAlert
nature.com/articles/s4156…

Revised Stage Group Definitions:

Stage IIB: Previously defined as T3N0M0, this stage has been reclassified to T1-T2N1M0. This change reflects a more accurate representation of prognosis where tumor size and nodal status are considered more comprehensively.

Stage IIIA: Updated…

Out in Journal for ImmunoTherapy of Cancer

A multi-center study on the timing of IO infusion and efficacy ⌚️⌚️

☑️201 patients with mRCC
☑️Better OS and PFS with IO infusions before noon 🌞🌞
☑️Support studies in melanoma and NSCLC ➕➕
🔎Could be preferable in daily practice until further evidence…

📘Targeting KRAS in Colorectal Cancer
JCO Oncology Practice

✅A precision review

➡️KRAS inhibitors for G12C mutants
➡️Allele-specific inhibitors
➡️panKRAS and panRAS inhibitors
➡️Unique biological features of RAS-mutant CRC
✅Novel therapeutic avenues

👉doi.org/10.1200/OP.23.……

Thanks for contribution of surgery trials 💪🏻😊

📖DCIS: Balance between overtreatment and undertreatment
The Lancet

✅A comprehensive review
➡️natural history of DCIS
➡️challenges in the detection and diagnosis
➡️prognostic and therapeutic biology
➡️tailored surgical management
➡️Radiotherapy
➡️Systemic treatment…

🗓️Roundup of the last year-Potentially practice changing trials: Gynecologic cancers 🚺

✅Endometrial cancer
✔️NRG-GY018
✔️ENGOT-EN6/GOG-3031/NSGO-RUBY
✔️ENGOT-EN5/GOG-3055/SIENDO
✔️AtTEnd
✔️DUO-E

✅Cervical
✔️GCIG INTERLACE
✔️NRG-GY017
✔️ENGOT-cx11/GOG-3047/KEYNOTE-A18…

💊Bispecific ADCs: A potential next generation game changer

➡️Bispecific ADCs in clinical development, issues to consider for a bispecific ADC 👇

✅A very nice post by Dr. Dowdy Jackson

👉 jackson-consulting-group.com/post/bispecifi…

Paolo Tarantino Enes Erul MD ASPET Mid-Atlantic Pharmacology Society
#Cancer #Oncology …

📢Pembrolizumab monotherapy for high-risk NMIBC without carcinoma in situ and unresponsive to BCG
KEYNOTE-057, cohort B
The Lancet Oncology

✅Primary endpoint ➡️12-month disease-free survival: 43·5% (95% CI 34·9–51·9)
🚨14% had grade 3 or 4 treatment-related AE

✅Potentially an…

Experiencing a scientific feast on molecular oncology with insights from experts... Time for some active relaxation this weekend! 🧬🔬 Many thanks to TARGED #MedTwitter #Oncology

Prof. Yüksel Ürün has given a extremely educational speech on molecular biomarkers in urothelial cancer in Molecular Oncology meeting of TARGED

❓PD-L1 is not as useful as expected

❗️Upper urethelial tract cancers has different molecular features, thus may have…

📢oxaliplatin-based HIPEC resulted in superior overall and recurrence-free survival compared to mitomycin C-based HIPEC in patients with peritoneal metastasized colorectal cancer undergoing cytoreductive surgery. BJS Open OncoAlert Cihangir Akyol, MD Erman Akkus

📢 I am thrilled to share our latest study just published in Cancers MDPI

✅Royal Marsden Hospital (RMH) score predicts cancer survival beyond clinical trials

💥Promising tool for real-world patient care

A huge thank you to Deniz Can Guven 🙏

OncoAlert OncoDaily

📢Adjuvant imatinib in high risk GIST:
3 years or 6years?

IMADGIST ESMO - Eur. Oncology Virtual Plenary, Annals of Oncology

✅DFS was significantly superior with 6-year imatinib
HR: 0.40 [0.20-0.69], p=0.0008

➡️136 patients
➡️Localized GIST with KIT expression, a R0 or R1 surgery, and a…

📘Low-Grade Glioma Management
ASCO Educational Book

✅IDH1/2 and BRAF are frequently altered, should be tested in all patients
✅IDH inhibitor therapy may be considered in patients who have not received radiation or chemotherapy
✅BRAF inhibitor therapy is an appropriate…

💉Adding relatlimab to nivolumab+ ChT in first line treatment of advanced gastric and GEJ cancer
RELATIVITY-060 Journal of Clinical Oncology

❌Negative study
➡️ORR: 48% vs 61%
➡️mPFS: 7.0 vs 8.3 mo, HR: 1.41 (0.97 to 2.05)
➡️mOS: 13.5 vs 16.0 mo, HR, 1.04: (0.70 to 1.54)…

The OncoAlert weekly round-up is here 🥁🥁🥁🥁

Make sure to REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… ☑️☑️

What to expect this week 🤓🤓
Updates from practice-changing trials 💉💉
Several pivotal policy and prevention trials 🆕🆕

Greatly summarized by…